CM19XA: A Novel Biologic for Cancer Treatment

CM19XA: A Novel Biologic for Cancer Treatment ID: 2022-002

CM19XA is a groundbreaking biologic designed to inhibit cancer metastasis and promote targeted eradication of cancer cells through enhanced CAR-T cell therapy.

Technology Overview:

CM19XA is an innovative biologic that integrates three functional domains: pHLIP for targeting cancer cells in acidic environments, JAM-A for reducing cell proliferation and migration by enhancing cell-to-cell adhesion, and CD19 for marking cancer cells for destruction by anti-CD19 CAR-T cells. This biologic has shown promising results in reducing cancer cell proliferation and migration in CAL27 cell assays and exhibits specificity by targeting only cancer cells, leaving non-cancerous cells unaffected. Its modular design allows for customization to target various cancer types effectively.

Key Advantages

Effectively reduces cancer cell proliferation and migration.
Targets cancer cells specifically without affecting non-cancerous cells.
Modular design allows for adaptability across different cancer types.
Enhances the efficacy of existing CAR-T cell therapies by preventing metastasis.
Promotes targeted eradication of cancer cells.

Problems Solved

Uncontrolled proliferation and migration of cancer cells leading to metastasis.
Lack of specificity in targeting cancer cells, resulting in damage to healthy cells.
Inefficiency of existing CAR-T cell therapies in preventing metastasis.

Market Applications

Oncology treatments, specifically for cancers amenable to CAR-T cell therapy.
Personalized medicine through the biologic's adaptability to different cancer biomarkers.
Combinatorial therapies with existing cancer treatment modalities to enhance efficacy and specificity.

Additional Information

Technology ID: 2022-002
Sell Sheet: Download the Sell Sheet here
Date Published: March 21, 2025